Critics Say Biologics Bill Doesn't Protect Innovators
Critics of legislation that would provide a pathway for copies of biologic drugs to make their way to the marketplace say the proposal allows no market exclusivity and unfairly tilts the...To view the full article, register now.
Already a subscriber? Click here to view full article